Coherus Oncology (CHRS) Interest Expenses (2013 - 2026)
Coherus Oncology (CHRS) posted Interest Expenses of $2.2 million for Q1 2026, down 72.43% sequentially from $7.9 million in Q4 2025, and down 75.06% YoY from $8.8 million in Q1 2025.
Coherus Oncology (CHRS) Interest Expenses (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Interest Expenses for 14 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Interest Expenses fell 75.06% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 120.92% YoY) and the FY2025 annual result came in at $368.1 million, down 10.83% from the prior year.
- Interest Expenses slipped to $2.2 million in Q1 2026 per CHRS's latest filing, from $7.9 million in the prior quarter.
- Over five years, Interest Expenses peaked at $29.9 million in Q4 2022 and troughed at $2.2 million in Q1 2026.
- A 5-year average of $7.9 million and a median of $7.5 million in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2026: Interest Expenses jumped 415.9% in 2022, then plunged 75.06% in 2026.
- Over 5 years, Interest Expenses stood at $29.9 million in 2022, then tumbled by 64.47% to $10.6 million in 2023, then sank by 39.55% to $6.4 million in 2024, then advanced by 23.52% to $7.9 million in 2025, then tumbled by 72.43% to $2.2 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $2.2 million, $7.9 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.32 Mn |
| Jun 30, 2026 | 2.32 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 7.93 Mn |
| Dec 31, 2025 | 7.93 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 8.76 Mn |
| Mar 31, 2025 | 8.76 Mn |
| Dec 31, 2024 | 6.42 Mn |
| Dec 31, 2024 | 6.42 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |